Various members of the TGF-b superfamily of signaling molecules are known to have important roles in mesoderm patterning and differentiation during vertebrate and invertebrate embryogenesis. Here we characterize a new TGF-b member from Drosophila, Myoglianin, that is most closely related to the vertebrate muscle differentiation factor Myostatin and to vertebrate BMP-11. Northern analysis shows that myoglianin is expressed throughout the Drosophila life cycle. In situ hybridization detects maternally-derived transcripts that are enriched in the pole plasm and later become enclosed in the pole cells. Between stages 11 and 14, myoglianin mRNA is exclusively detected in glial cells and their precursors. Following stage 14, high levels of myoglianin expression are observed in the developing somatic muscles as well as in visceral muscles and cardioblasts. We also show that the zygotic expression of a recently described Drosophila activin, which maps to the same interval 102 on chromosome 4 as myoglianin, is restricted to the developing central and peripheral nervous system. q
Results and discussion
A conceptual ORF, derived from an unpublished EST clone, with sequence similarity to bone morphogenetic proteins (BMPs) was released by the Berkeley Drosophila Genome Project (BDGP) and this information was used to isolate cDNAs for this gene. The largest cDNA, with a 2.9 kb insert, contains a long ORF encoding a 598 amino acid protein (Fig. 1A) . In a BLAST database search, the predicted protein sequence of this gene, which we named myoglianin, shows the highest degree of similarity to three different vertebrate members of the TGF-b superfamily of secreted signaling molecules, BMP-11, Myostatin, and BMP-3, as well as a weaker degree of similarity with Dpp, the best matching Drosophila TGF-b superfamily member. As with all members of this superfamily, the full-length myoglianin sequence possesses a proteolytic processing site (RRKR, matching the RXXR consensus site) and a nearly invariant pattern of seven cysteines in the carboxy-terminal portion of the ORF that corresponds to the mature processed protein (see alignment of the mature protein sequences in Fig. 1B ).
The two proteins most homologous to Myoglianin are vertebrate BMP-11 and Myostatin, which are both 46% identical. BMP-11 is somewhat more homologous, with 68% similar and identical residues as compared to 65% for Myostatin. At present, there is no published data regarding the BMP-11 gene, whereas the pattern of expression and function of Myostatin has been characterized in vertebrates. Initially isolated in mice , myostatin is expressed in various vertebrate species in the developing muscles of embryos and then in all skeletal muscles of adults Gonzalez-Cadavid et al., 1998; Ji et al., 1998) . Targeted disruption of the gene in mice results in a large increase in the size of all adult skeletal muscles , strongly suggesting that myostatin acts to negatively regulate skeletal muscle growth in vertebrates. This is also supported by the ®nding that double-muscled cattle breeds contain mutations in their myostatin genes (Grobet et al., 1997; Kambadur et al., 1997; . Vertebrate BMP3 (osteogenin), which is 44% identical (62% plus similar residues) to mature myoglianin, is a regulator of osteogenesis and chondrogenesis (Sampath et al., 1987; Wozney et al., 1988; Vukicevic et al., 1989) .
Developmental Northern analysis using the 2.9 kb cDNA insert as a probe detected a band of approximately 3 kb ( 2O). This transcript is present at a high level in 0±2 h embryos, indicating maternal deposition of the transcript, and later peaks of expression levels are seen in 12±24 h embryos and in adults.
Using in situ hybridization, the pattern of myoglianin expression was examined during Drosophila development. In preblastoderm embryos, a high level of maternallydeposited myoglianin transcripts is uniformly distributed throughout the embryo, with an even higher localization at the very posterior end ( Fig. 2A) . This posterior concentration of message appears to be in the pole plasm since embryos laid by females homozygous for the oskar 6 mutation lack pole plasm (Lehmann and Nu Èsslein-Volhard, 1986 ) and do not show localization of myoglianin transcripts at the posterior (Fig. 2B ). In stage 6 gastrulation embryos, the localized pole plasm message appears to be incorporated into pole cells, while the overall level of maternal transcript in the rest of the embryo has decreased (Fig.  2C ). Zygotic expression of myoglianin is ®rst observed in stage 11 embryos in what appear to be glial precursor cells (Fig. 2D) . By stage 14, strong expression is evident in glial cells (CNS and exit/peripheral glia; Fig. 2E ,F). This glial expression of myoglianin is completely lost in stage 15 embryos and expression is now detected in the somatic (Fig. 2G) , visceral, and heart (data not shown) musculature, which then persists through late embryogenesis (Fig. 2H) . In third instar larvae, the only speci®c pattern of expression observed is in the brain and ventral nerve cord, where a particular subset of cells, presumably glial cells, express myoglianin (Fig. 2I) .
Veri®cation that the stage 14 staining was in glial cells was demonstrated by two methods. First, wild type embryos were¯uorescently in situ hybridized for myoglianin and uorescently stained with anti-repo antibody, which labels the nuclei of all glial cells except for the midline glia (Campbell et al., 1994; Xiong et al., 1994; Halter et al., 1995) . Staining of glial cells in a late stage 14 wild type embryo with both probes is observed, as is myoglianin in situ staining of the somatic muscles (Fig. 2J) . Second, embryos from a line carrying a null mutation of the glial cells missing (gcm) (Hosoya et al., 1995; Jones et al., 1995; Vincent et al., 1996) gene were in situ hybridized for myoglianin and stained with the anti-repo antibody using chromogenic substrates. As with the ®rst method, wild type embryos demonstrate labelling of the glial cells by both probes as well as the staining of the somatic muscles by the myoglianin probe (Fig. 2K) . Homozygous gcm null mutants, on the other hand, lack both the myoglianin in situ and anti-repo staining of glia while still possessing myoglianin staining of the muscles, con®rming that myoglianin is expressed in embryonic glial cells (Fig. 2L) .
As determined by polytene chromosome in situ hybridization, the myoglianin gene maps to the cytogenetic location 102C on the fourth chromosome (data not shown). Another recently isolated Drosophila TGF-b family member, an activin b homolog, also maps to the fourth chromosome at 102F (Kutty et al., 1998) . As a comparison to myoglianin, we examined the previously undescribed expression pattern of this Drosophila activin b homolog during embryogenesis by in situ hybridization. Expression of this gene is initially observed in neuroblasts and sensory organ precursors at stage 11 (Fig. 2M ) and subsequently in both CNS and PNS neuronal cells in later embryos (Fig. 2N) . The CNS staining in late embryos appears to be throughout the ventral nerve cord. Speci®c staining in other embryonic tissues was not seen.
In conclusion, we have isolated myoglianin, a novel Drosophila member of the TGF-b superfamily that is expressed in muscle and glial cells during embryogenesis. The expression of myoglianin in embryonic muscles is interesting in light of the similarity of its protein sequence to the vertebrate Myostatins, which appear to negatively regulate skeletal muscle mass. Whether myoglianin is functionally related and acts similarly to regulate muscle development in Drosophila is presently unclear, especially since myoglianin is expressed in all three muscle types (somatic, visceral, and heart) and in glia, whereas myostatin appears to be restricted to vertebrate skeletal muscles. The isolation and phenotypic analysis of mutations in the myoglianin gene should enable the elucidation of its function during Drosophila embryogenesis and its evolutionary relationship to myostatin.
Materials and methods
Degenerate primers corresponding to the amino acid sequences CCSPTKM and VEGCSCS located at the carboxy-terminal end of an EST clone (CK01508) ORF were used to amplify an approximately 100 bp fragment from Drosophila genomic DNA. Sequencing con®rmed that it contained the matching portion of the EST clone ORF sequence that was temporarily posted on the BDGP web site. A 4±8 h embryonic cDNA plasmid library (Brown and Kafatos, 1988) was screened with this PCR fragment to obtain cDNA clones. The 2.9 kb insert was sequenced on both strands. Northern hybridization with this cDNA insert 1 RNA from 0±2 h, 2±4 h, 4±8 h, 8±12 h, and 12±24 h embryos, from ®rst (L1), second (L2), and third (L3) larvae, from pupae (P), and from adult females (F) and males (M) were probed with the 2.9 kb cDNA insert. The position of RNA size markers (obtained from a previous hybridization of the same blot) is indicated on the left in kilobases. For the loading control of a similar Northern blot loaded with exactly the same amount of these poly(A)
1 RNAs see Fig. 2 of Azpiazu and Frasch (1993). was done as described in Azpiazu and Frasch (1993) . In situ hybridization and antibody staining were done for embryos as described in Azpiazu and Frasch (1993); Frasch (1995) ; in addition, in situ hybridizations were carried out at 558C with DIG-labelled T7 RNA transcripts of the myoglianin 2.9 kb cDNA insert and a 1.3 kb Drosophila activin b genomic DNA fragment (generated by PCR from positions 1697-3039 of a P1 clone (Kutty et al., 1998) which was a gift from R. Krishnan Kutty) . Fluorescent double-labelling of embryos was done by tyramide-ampli®ed myoglianin in situ hybridization (¯uorescein) and tyramide-ampli®ed anti-repo antibody staining (Cy3) using the appropriate TSA kit (NEN). The th st kni ri-1 roe osk 6 p p /TM3,Sb stock was obtained from the Bloomington stock center. Mouse anti-repo antibody and the gcm D P1 /CyO, elav-lacZ stock were gifts of Brad W. Jones.
